Compare Crispr Therapeutics AG (CRSP) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kroger Co — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Kroger Co trades at $58.75 (market cap $35.99B). The key difference: Kroger Co is far larger — about 7.2× Crispr Therapeutics AG's market cap, and Kroger Co pays a 2.45% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KR | |
|---|---|---|
Market Cap | $4.97B | $35.99B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $75.60 |
52-Week Low | $44.34 | $55.53 |
Enterprise Value | $3.32B | $56.08B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Kroger (KR) trades at $59.31, down 2.03% today, with technical indicators showing bearish momentum. The company maintains stable revenue around $147B with improving net margins (1.81% in 2025) and recently announced a $1.65B acquisition of Giant Eagle to expand Midwest presence. Strong cash flow generation ($2.08B net in 2025) supports dividend payments and strategic investments.
Kroger presents a mixed outlook with attractive valuation metrics (P/S 0.26) and analyst consensus target of $68.63 offering 16% upside potential. However, competitive pressures, recent earnings miss, and bearish technical signals warrant caution. The Giant Eagle acquisition provides growth opportunity but integration risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
